JW Lifescience Corporation (KRX:234080)
11,090
-210 (-1.86%)
Aug 21, 2026, 3:30 PM KST
JW Lifescience Revenue
JW Lifescience had revenue of 63.25B KRW in the quarter ending June 30, 2026, with 1.58% growth. This brings the company's revenue in the last twelve months to 253.71B, up 4.13% year-over-year. In the year 2025, JW Lifescience had annual revenue of 257.83B with 15.89% growth.
Revenue (ttm)
253.71B
Revenue Growth
+4.13%
P/S Ratio
0.68
Revenue / Employee
854.23M
Employees
297
Market Cap
171.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 257.83B | 35.35B | 15.89% |
| Dec 31, 2024 | 222.48B | 15.62B | 7.55% |
| Dec 31, 2023 | 206.86B | 17.93B | 9.49% |
| Dec 31, 2022 | 188.93B | 19.11B | 11.26% |
| Dec 31, 2021 | 169.82B | -13.70B | -7.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 961.64B |
| Daewon Pharmaceutical | 614.64B |
| Ilyang Pharmaceutical Co.,Ltd | 277.96B |
| Whan In Pharm | 273.47B |
| Daihan Pharmaceutical | 211.44B |
| REYON Pharmaceutical | 143.37B |
| Hana Pharm | 139.33B |
| Hyundai Pharmaceutical | 108.14B |